Loading lessons…
Peptide learning paths
Learn peptides step by step
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
288lessons
8paths
0day streak
0%explored
Start your first lesson
Choose a learning path below or search the library. Progress saves in your browser.
Prefer timeline chaos? Peptide X Quiz · Literacy certify
Learning paths
Pick a track — progress rings update as you complete lessons.
10 lessons
7mSafetyIntermediate
Telehealth Peptide Prescribing After the 2026 PCAC Votes
A favorable advisory vote is not permission to prescribe or compound. Here is the practical standard telehealth clinics should use after the 2026 PCAC meeting.
8mSafetyIntermediate
BPC-157 Advisory Review: What It Means for Compounding Access in 2026
BPC-157 is still a research compound, but the advisory review makes one thing clear: access, sourcing, and evidence quality now matter as much as the mechanism.
8mSafetyIntermediate
BPC-157's Regulatory Momentum Is Changing How People Read the Evidence
The regulatory story matters because it changes what you can trust, what you should track, and why supply chain quality now sits beside mechanism in the BPC-157 debate.
8mResearchAdvanced
FDA Peptide Compounding Review: What the Seven-Peptide Debate Means for Buyers and Clinics
Regulation does not settle the peptide debate by itself. It forces clearer questions about sourcing, safety, evidence, and who is responsible when claims move faster than data.
8mSafetyIntermediate
FDA July 2026 Peptide Review: How to Track BPC-157, TB-500, MOTS-C, Semax, and Epitalon Without the Hype
The July 2026 FDA peptide review is important, but it is not an approval event. Here is how to track the meeting, sourcing changes, and protocol decisions without confusing policy movement with clinical proof.
7mResearchAdvanced
Peptide Regulation and Sourcing Safety in 2026
The biggest peptide trend in 2026 may not be a molecule. It may be oversight, sourcing quality, and the ability to separate evidence from marketing.
8mResearchAdvanced
Wellness Peptides and the Evidence Gap: What ECRI and ISMP Warned
A new ECRI and ISMP warning says popular wellness peptides are being marketed faster than the evidence can support. Here is how to separate compound science from product risk.
8mResearchAdvanced
Health Canada Peptide Warning: What Buyers Should Know
Health Canada's 2026 public advisory names unauthorized injectable peptides sold online and explains why product quality, legal status, and medical supervision matter.
8mResearchAdvanced
FDA Warning Letters Signal a New Era for Peptide Buyers
Seven FDA warning letters in April 2026 show regulators are paying closer attention to online peptide sellers, especially research-use-only marketing that looks like consumer health claims.
8mStart hereBeginner
503a vs 503b vs Unapproved Peptide Status: What's the Difference?
Confused about peptide compounding categories? This guide breaks down 503a compounding pharmacies, 503b outsourcing facilities, and why “research use only” is not a consumer pathway PeptIQ endorses.
Also available at /blog for legacy links.